TransCode Therapeutics Expands Immuno-Oncology Pipeline with Polynoma Acquisition TransCode Therapeutics announced a significant acquisition of Polynoma, enhancing its oncology portfolio with a unique immuno-oncology solution. This transaction includes a $25 million financing to support future advancements.

TransCode Therapeutics Expands Immuno-Oncology Pipeline with Polynoma Acquisition #United_States #San_Diego #TransCode_Therapeutics #Polynoma #CK_Life_Sciences